Compare NIO Inc. (NIO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs 10X Genomics Inc — how do they compare? NIO Inc. trades at $3.47 (market cap $8.62B), while 10X Genomics Inc trades at $78.75 (market cap $10.07B). The key difference: 10X Genomics Inc is the larger of the two by market cap, and 10X Genomics Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and 10X Genomics Inc for 92 Days on average.
| NIO | TXG | |
|---|---|---|
Market Cap | $8.62B | $10.07B |
Volume | 39,648,517 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $97.74 |
52-Week Low | $3.37 | $11.48 |
Typical Hold Time | 81 Days | 92 Days |
Enterprise Value | $6.52B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.54, down 55% from its 52-week high, with a bearish technical signal despite recent earnings beats. The company shows improving revenue growth (2025: $87.5B) and narrowing losses (net margin: -17.8% in 2025 vs -34.5% in 2024), supported by a strategic battery-swap partnership with Geely. However, negative cash flow (-$10.9B in 2024) and high debt ($20.6B total debt) remain concerns.
The stock offers speculative upside to the $6.23 analyst target (76% potential) but faces significant execution risks in China's competitive EV market. Investors must weigh improving fundamentals against persistent profitability challenges and macroeconomic headwinds.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
